À¯·´ÀÇ ÇÙ»ê »ùÇà Á¶Á¦ ½ÃÀå ±Ô¸ð´Â 2022³â 13¾ï 740¸¸ ´Þ·¯¿¡¼ ¿¹Ãø ±â°£ µ¿¾È 9.89%ÀÇ CAGRÀ» ±â·ÏÇϸç 2032³â¿¡´Â 33¾ï 5,670¸¸ ´Þ·¯ ±Ô¸ð·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
´Ù¾çÇÑ ÀÇ·á ºÐ¾ß¿¡¼ ÇÙ»ê ºÐÀÚÀÇ »ç¿ë ±âȸ°¡ Áõ°¡ÇÔ¿¡ µû¶ó À¯·´ÀÇ ÇÙ»ê »ùÇà Á¶Á¦ ½ÃÀå ¼ºÀå¿¡ ¹ÚÂ÷¸¦ °¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ, Â÷¼¼´ë ¿°±â¼¿ ºÐ¼®(NGS)°ú °°Àº ´Ù¿î½ºÆ®¸² ¾ÖÇø®ÄÉÀ̼ÇÀÇ ¼ö¿ä Áõ°¡¿Í ÇÙ»ê ÃßÃâ/ºÐ¸® ±â¼ú°ú °ü·ÃµÈ ±âŸ ¹ßÀüÀÌ ÀÌ Áö¿ªÀÇ ÇÙ»ê ½Ã·á Àüó¸® ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.
¶ÇÇÑ, ½Å¼ÓÇÑ Áø´Ü Á¤º¸¿Í Ç¥ÀûÈµÈ È¯ÀÚ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡µµ ÀÌ ½ÃÀåÀÇ ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¼ö¿ä¸¦ ÃæÁ·½Ã۱â À§ÇØ ÀÚµ¿ ÇÙ»ê »ùÇà Á¶Á¦ ¿öÅ©½ºÅ×À̼ÇÀ» Æ÷ÇÔÇÑ ´Ù¾çÇÑ ºÐÀÚ ÀýÂ÷°¡ °³¹ßµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, »ùÇà Á¶Á¦´Â Á¤¹ÐÀÇ·á¿¡¼ Áß¿äÇÑ ¿ªÇÒÀ» ´ã´çÇϰí ÀÖÀ¸¸ç, °³ÀÎ ¸ÂÃãÇü Ä¡·áÀÇ ¾ÈÁ¤ÀûÀ̰í È¿°úÀûÀÎ Àû¿ëÀ» º¸ÀåÇÕ´Ï´Ù.
À¯·´ÀÇ ÇÙ»ê »ùÇà Á¶Á¦ ½ÃÀåÀ» Á¶»çÇßÀ¸¸ç, ½ÃÀå °³¿ä, ½ÃÀå ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â °¢Á¾ ¿µÇâ¿äÀÎ ºÐ¼®, ±ÔÁ¦ ȯ°æ, ½ÃÀå ±Ô¸ð ÃßÀÌ ¹× ¿¹Ãø, °¢Á¾ ºÎ¹®º°¡¤Áö¿ªº°¡¤ÁÖ¿ä ±¹°¡º° »ó¼¼ ºÐ¼®, °æÀï »óȲ, ÁÖ¿ä ±â¾÷ ºÐ¼® µîÀÇ Á¤º¸¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
ÁÖ¿ä ½ÃÀå Åë°è |
¿¹Ãø ±â°£ |
2022-2032³â |
2022³â Æò°¡ |
13¾ï 740¸¸ ´Þ·¯ |
2032³â ¿¹Ãø |
33¾ï 5,670¸¸ ´Þ·¯ |
CAGR |
9.89% |
½ÃÀå ¼¼ºÐÈ
¼¼ºÐÈ 1: ±¹°¡º°
- µ¶ÀÏ
- ÇÁ¶û½º
- ÀÌÅ»¸®¾Æ
- ½ºÆäÀÎ
- ¿µ±¹
- ±âŸ À¯·´
¸ñÂ÷
Á¦1Àå ½ÃÀå
- Á¦Ç° Á¤ÀÇ
- ½ÃÀå ¹üÀ§
- Á¶»ç ¹æ¹ý
- ½ÃÀå °³¿ä
- ½ÃÀå Á¤ÀÇ
- ½ÃÀå ±Ô¸ð¡¤¼ºÀå °¡´É¼º
- ´ëÀÀ °¡´ÉÇÑ ½ÃÀå ±Ô¸ð¡¤¼ºÀå °¡´É¼º
- Âü¿© »ç¾÷ÀÚ »óȲ
Á¦2Àå ÇÙ»ê »ùÇà Á¶Á¦ ½ÃÀå : ¾÷°è ºÐ¼®
- ¾÷°è ÀλçÀÌÆ®
- ƯÇ㠺м®
- COVID-19¿¡ ÀÇÇÑ ÇÙ»ê »ùÇà Á¶Á¦ ½ÃÀå¿¡ ´ëÇÑ ¿µÇâ
Á¦3Àå ÇÙ»ê »ùÇà Á¶Á¦ ½ÃÀå : ½ÃÀå ¿ªÇÐ
- °³¿ä
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
- ´Ù¾çÇÑ Ä¡·á ºÐ¾ßÀÇ ÇÙ»ê ºÐÀÚ »ç¿ë Áõ°¡
- ÇÙ»ê ÃßÃ⡤´Ü¸® ±â¼ú Áøº¸
- ÀÚµ¿ »ùÇà Á¶Á¦ ¿öÅ©½ºÅ×À̼ÇÀÇ ÀÌÁ¡
- Â÷¼¼´ë ½ÃÄö½Ì(NGS) µîÀÇ ´Ù¿î½ºÆ®¸² ¿ëµµ ¼ö¿ä Áõ°¡
- ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
- ÀÚµ¿ ¿öÅ©½ºÅ×À̼ÇÀÇ °íºñ¿ë¼º
- ¾ö°ÝÇÑ ±ÔÁ¦ ±âÁØ
- ½ÃÀå ±âȸ
- ÀÚµ¿ »ùÇà Á¶Á¦ ¿öÅ©½ºÅ×À̼ÇÀÇ ±â¼ú Áøº¸
- ¹ÙÀÌ¿À¹ðÅ©¸¦ À§ÇÑ ÇÙ»ê ºÐÀÚ
- ½ÅÈï ±¹°¡ÀÇ ¼ºÀå
Á¦4Àå °æÀï »óȲ
- °³¿ä
- ±â¾÷ Àü·«
- »ç¾÷ Àü·«
- ½ÃÀå Á¡À¯À² ºÐ¼®
Á¦5Àå ÇÙ»ê »ùÇà Á¶Á¦ ½ÃÀå : Áö¿ªº°
- °³¿ä
- À¯·´
- µ¶ÀÏ
- ÇÁ¶û½º
- ¿µ±¹
- ÀÌÅ»¸®¾Æ
- ½ºÆäÀÎ
- À¯·´ÀÇ ±âŸ Áö¿ª
Á¦6Àå ±â¾÷ °³¿ä
- Endress+Hauser Group Services AG(Analytik Jena GmbH)
- Eppendorf SE
- F. Hoffmann-La Roche Ltd
- Merck KGaA
- QIAGEN
- Tecan Trading AG
ksm
“The Europe Nucleic Acid Sample Preparation Market Expected to Reach $3,356.7 Million by 2032.”
Introduction to Europe Nucleic Acid Sample Preparation Market
The Europe nucleic acid sample preparation market is projected to reach $3,356.7 million by 2032 from $1,307.4 million in 2022, growing at a CAGR of 9.89% during the forecast period 2022-2032. The increased use of nucleic acid molecules in a variety of medicinal contexts is expected to fuel the growth of the nucleic acid sample preparation market in Europe. Furthermore, the region's nucleic acid sample preparation market is expanding due in large part to the increased demand for downstream applications such as next-generation sequencing (NGS) and other associated developments in nucleic acid extraction/isolation techniques.
KEY MARKET STATISTICS |
Forecast Period | 2022 - 2032 |
2022 Evaluation | $1,307.4 Million |
2032 Forecast | $3,356.7 Million |
CAGR | 9.89% |
Market Introduction
The nucleic acid sample preparation market in Europe is currently advancing to meet the increasing demand for prompt diagnostic information and targeted patient treatment. Various molecular procedures, including automated nucleic acid sample preparation workstations, have been developed to address this need. Furthermore, sample preparation plays a crucial role in precision medicine, ensuring the secure and effective application of personalized therapies. The market provides a diverse range of universal products with varying maximum throughputs, innovations, time durations, and other attributes, prompting companies to explore inventive ways to differentiate themselves. Notably, manufacturers have recently introduced application-specific nucleic acid purification devices and liquid handlers to cater to specific needs in the European market.
Impact
One of the main reasons for the anticipated expansion of the nucleic acid sample preparation market in the upcoming years is the rise in the use of nucleic acid molecules in several therapeutic areas. Sample preparation is typically an important phase in the accurate analysis of nucleic acids. Nuclease protection is one of the most important aspects to consider while processing nucleic acid samples. Nucleic acid extraction and isolation is the first stage in the area of molecular biology research, followed by recombinant procedures.
Market Segmentation:
Segmentation 1: by Country
- Germany
- France
- Italy
- Spain
- U.K.
- Rest-of-Europe
In 2021, Europe accounted for a share of 31.14% of the nucleic acid sample preparation market. The presence of some of the prominent companies in the market is a key factor driving the growth of the Europe region.
Recent Developments in the Europe Nucleic Acid Sample Preparation Market
- In November 2022, RevoluGen, a U.K.-based genomics company, announced that it had entered into an agreement with Tecan Trading AG, a pioneer and industry leader in laboratory automated processes, for the production and supply of Tecan's 96-well filter plates for use in RevoluGen's automated Fire Monkey High Molecular Weight (HMW)-DNA extraction kits.
How can this report add value to an organization?
Growth/Marketing Strategy: Nucleic acid sample preparation is being used for genomics, proteomics, and other applications. Various companies are providing consumables and systems aid in the diagnosis of various therapeutic areas, which is also the key strategy for market players to excel in the current Europe nucleic acid sample preparation market.
Competitive Strategy: Key players in the Europe nucleic acid sample preparation market have been analyzed and profiled in the study, including manufacturers involved in new product launches, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the Europe nucleic acid sample preparation market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analysing company coverage, product portfolio, and market penetration.
Some of the prominent names established in this market are:
- Endress+Hauser Group Services AG
- Eppendorf SE
- F. Hoffmann-La Roche Ltd.
|
- Merck KGaA
- QIAGEN
- Tecan Trading AG
|
Table of Contents
1 Market
- 1.1 Product Definition
- 1.1.1 Inclusion and Exclusion Criteria
- 1.2 Market Scope
- 1.2.1 Scope of the Study
- 1.2.2 Key Questions Answered in the Report
- 1.3 Research Methodology
- 1.3.1 Nucleic Acid Sample Preparation Market: Research Methodology
- 1.3.2 Data Sources
- 1.3.2.1 Primary Data Sources
- 1.3.2.2 Secondary Data Sources
- 1.3.3 Market Estimation Model
- 1.3.4 Criteria for Company Profiling
- 1.4 Market Overview
- 1.4.1 Market Definition
- 1.4.2 Market Footprint and Growth Potential, $Million, 2021-2032
- 1.5 Addressable Market Size and Growth Potential ($Million), 2021-2032
- 1.6 Industry Participants Landscape
2 Nucleic Acid Sample Preparation Market, Industry Analysis
- 2.1 Industry Insights
- 2.1.1 Legal Requirements and Framework in Europe
- 2.2 Patent Analysis
- 2.2.1 Patent Filing Trend
- 2.2.2 Patent Analysis (by Year)
- 2.2.3 Patent Analysis (by Country)
- 2.2.4 Patent Analysis (by Region)
- 2.3 Impact of COVID-19 on the Nucleic Acid Sample Preparation Market
3 Nucleic Acid Sample Preparation Market: Market Dynamics
- 3.1 Overview
- 3.2 Market Drivers
- 3.2.1 Increasing Use of Nucleic Acid Molecules in Various Therapeutic Areas
- 3.2.2 Advancement in the Nucleic Acid Extraction/Isolation Techniques
- 3.2.3 Advantages of Automated Sample Preparation Workstations
- 3.2.4 Increasing Demand for Downstream Applications such as Next-Generation Sequencing (NGS)
- 3.3 Market Restraints
- 3.3.1 High Cost of Automated Workstations
- 3.3.2 Rigid Regulatory Standards
- 3.4 Market Opportunities
- 3.4.1 Technological Advancements in Automated Sample Preparation Workstations
- 3.4.2 Nucleic Acid Molecules for Biobanking in Healthcare
- 3.4.3 Growth in Emerging Nations
4 Competitive Landscape
- 4.1 Overview
- 4.2 Corporate Strategies
- 4.2.1 Mergers and Acquisitions
- 4.2.2 Synergistic Activities
- 4.2.3 Business Expansions
- 4.3 Business Strategies
- 4.4 Market Share Analysis
5 Nucleic Acid Sample Preparation Market, by Region ($Million), 2021-2032
- 5.1 Overview
- 5.2 Europe
- 5.2.1 Germany
- 5.2.2 France
- 5.2.3 U.K.
- 5.2.4 Italy
- 5.2.5 Spain
- 5.2.6 Rest-of-Europe
6 Company Profiles
- 6.1 Overview
- 6.2 Endress+Hauser Group Services AG (Analytik Jena GmbH)
- 6.2.1 Company Overview
- 6.2.2 Role of Endress+Hauser Group Services AG (Analytik Jena GmbH) in the Global Nucleic Acid Sample Preparation Market
- 6.2.3 Key Customers of the Company
- 6.2.4 Key Competitors of the Company
- 6.2.5 Business Strategies
- 6.2.6 Financials
- 6.2.7 Endress+Hauser Group Services AG (Analytik Jena GmbH): Revenue (by Region), $Million, 2019-2021
- 6.2.8 Key Insights about the Financial Health of the Company
- 6.2.9 Analyst Perspective
- 6.3 Eppendorf SE
- 6.3.1 Company Overview
- 6.3.2 Role of Eppendorf SE in the Nucleic Acid Sample Preparation Market
- 6.3.3 Key Competitors of the Company
- 6.3.4 Financials
- 6.3.5 Key Insights about the Financial Health of the Company
- 6.3.6 Analyst Perspective
- 6.4 F. Hoffmann-La Roche Ltd
- 6.4.1 Company Overview
- 6.4.2 Role of F. Hoffmann-La Roche Ltd in the Nucleic Acid Sample Preparation Market
- 6.4.3 Key Competitors of the Company
- 6.4.4 Business Strategies
- 6.4.5 Financials
- 6.4.6 Key Insights about the Financial Health of the Company
- 6.4.7 Analyst Perspective
- 6.5 Merck KGaA
- 6.5.1 Company Overview
- 6.5.2 Role of Merck KGaA in the Nucleic Acid Sample Preparation Market
- 6.5.3 Key Competitors of the Company
- 6.5.4 Financials
- 6.5.5 Key Insights about the Financial Health of the Company
- 6.5.6 Analyst Perspective
- 6.6 QIAGEN
- 6.6.1 Company Overview
- 6.6.2 Role of QIAGEN in the Nucleic Acid Sample Preparation Market
- 6.6.3 Key Customers of the Company
- 6.6.4 Key Competitors of the Company
- 6.6.5 Business Strategies
- 6.6.6 Financials
- 6.6.7 Key Insights about the Financial Health of the Company
- 6.6.8 Analyst Perspective
- 6.7 Tecan Trading AG
- 6.7.1 Company Overview
- 6.7.2 Role of Tecan Trading AG in the Nucleic Acid Sample Preparation Market
- 6.7.3 Key Customers of the Company
- 6.7.4 Key Competitors of the Company
- 6.7.5 Financials
- 6.7.6 Key Insights about the Financial Health of the Company
- 6.7.7 Analyst Perspective